Cheong PK, et al. - Experts conducted this single-center, double-blind, randomized controlled trial to evaluate the safety and effectiveness of imipramine in treatment-refractory functional dyspepsia. They enrolled consecutive patients with Rome II functional dyspepsia aged 18–80 years. At 12 weeks, the relief of global dyspepsia symptoms occurred in 35 of 55 patients on imipramine vs 19 of 52 on placebo. According to findings, for patients with functional dyspepsia refractory to both proton pump inhibitors and prokinetics, low-dose imipramine should be considered as a possible therapy. However, patients should be cautioned about the adverse event profile.